Introduction
The efficacy and safety of the mammalian target of rapamycin (mTOR) inhibitor everolimus in heart transplant patients has been extensively assessed in a series of trials over the last decade (1) .
There is a considerable body of evidence to indicate that everolimusbased immunosuppression can permit a marked reduction in exposure to cyclosporine (CsA) (1, 2), although robust evidence relating to tacrolimus reduction is still awaited. The efficacy of everolimus with reduced CsA has been convincingly demonstrated in randomized studies of de novo (3-6) and, to a lesser extent, maintenance (7, 8) heart transplant patients. However, its use outside the context of clinical trials remains largely restricted to maintenance patients in whom there is a reason to reduce or discontinue calcineurin inhibitor (CNI) exposure or in whom the direct antiproliferative properties of the drug are sought (3, 9). Indeed, the most frequent clinical trigger for everolimus introduction is declining renal function (7, This article reviews the available evidence on the de novo use of everolimus, weighing potential issues raised in recent randomized trials with the advantages that could be expected from long-term use of everolimus-based immunosuppression in heart transplant recipients.
Methodology
Multiple searches of the PubMed database were performed with no time or language restrictions using different combinations of the terms 'everolimus', 'heart', 'cardiac', 'transplantation', 'randomized' and 'mTOR'. The proceedings of the International Society for Heart and Lung Transplantation, the American Transplant Congress and the European Society for Organ Transplantation congresses during 2010-2012 were searched for 'everolimus' or 'mTOR'.
Efficacy of everolimus in de novo heart transplant recipients
The immunosuppressive potency of everolimus in de novo heart transplant recipients was first demonstrated in a randomized study by Eisen et al, in which everolimus at a fixed dose of 1.5mg or 3.0mg was associated with significantly superior efficacy outcomes to azathioprine, both in combination with standard-dose CsA (30) ( Table   1 ). Since then, following evidence from kidney (6, 31) and heart (4) transplantation showing that everolimus with reduced-exposure CsA offers equivalent efficacy to everolimus with standard-exposure CsA, and the advantage of therapeutic drug monitoring of everolimus (32), two randomized trials have assessed the use of everolimus with reduced-exposure CsA versus mycophenolate mofetil (MMF) with standard-exposure CsA (3, 5) in de novo heart transplant populations.
Both studies adjusted everolimus trough concentration according to pre-specified target ranges, as is now standard practice. Using an everolimus target range of 3-8ng/mL, the primary composite efficacy endpoint and the incidence of biopsy-proven acute rejection (BPAR) were similar in the everolimus and MMF treatment arms at 12 months post-transplant in each study (Table 1) . Retrospective, single-center analyses using everolimus (3-8ng/mL) with reduced CsA have also reported similar efficacy to MMF with standard CsA (25, 26) or tacrolimus (27, 29), including one series of 49 patients followed up for five years post-transplant (26). Higher everolimus exposure levels in CNI-treated patients may be inadvisable in view of an increased rate of early (<3 months) deaths in the recent A2310 study among patients randomized to a target concentration range of 6-12ng/mL (3). Use of IL-2 receptor antibody induction in this setting does not appear to be associated with safety concerns (28).
Only one trial has investigated the use of mTOR inhibition within a CNI-free regimen for de novo heart transplant patients, in a series of 20 patients with poor kidney function at time of transplant (GFR Within the mean follow-up of 500 days, by the end of follow-up 11 patients (55%) had experienced rejection. Such an approach is unlikely to become widely adopted except possibly as a temporary regimen in patients with significant renal impairment at the time of transplant. However, a low CNI regimen with everolimus from time of transplant, followed by early CNI withdrawal (≤3 months posttransplant), may be effective. This option is being explored in the SCHEDULE study, where patients either continue or discontinue CsA from week 7 post-transplant (NCT01266148). The results of the study are awaited with interest.
Potential advantages for de novo use of everolimus

Inhibition of CAV
CAV affects approximately 50% of heart transplant patients within the first five years after transplantation (34) and is a significant cause of morbidity and mortality (35). It is estimated that 30% of post-transplant deaths are caused by CAV (36). CAV is exacerbated by general risk factors including dyslipidemia, diabetes and hypertension that are highly prevalent in the transplant population, but also by transplantspecific factors including donor age and gender, ischemia/reperfusion injury, allograft rejection, CMV infection and HLA mismatch (37). Table 2 ).
Both studies used the change in MIT from baseline as the primary IVUS endpoint, and each showed that the increase was significantly smaller in the everolimus-treated patients, by two-fold or more.
Consistent with this, the secondary endpoint of incidence of CAV (defined as ≥0.5mm increase in MIT) was significantly lower in the everolimus cohorts (3, 30). In the trial comparing fixed-dose everolimus versus azathioprine, follow-up IVUS data from 24 months post-transplant showed that the benefit was maintained, although the strict IVUS protocol limited the number of patients for whom evaluable data were available (48). Other secondary IVUS endpoints also 
CMV infection
Development of CMV infection is more frequent following heart transplantation compared to other types of solid organ transplant (54).
The adverse clinical consequences of CMV infection following heart transplantation are well-recognized, and include increased risk of allograft rejection and infection, accelerated CAV progression and higher mortality (55, 56). Evidence from de novo kidney transplant populations has confirmed the incidence of CMV infection to be lower with mTOR inhibitors generally (57), and with everolimus specifically (58, 59), compared to MPA with standard-exposure CNI therapy.
Similarly, randomized trials of everolimus in de novo heart transplantation have consistently shown a low rate of CMV infection (3-5, 30, 60, 61) (Table 3) , and comparative trials versus MMF (3, 5, 60) or azathioprine (30, 61) have each reported a significantly lower rate of CMV infection in the everolimus treatment arms (58). Indeed, the incidence of CMV infection in de novo heart transplant recipients receiving everolimus with reduced-dose CsA appears to be less than half that seen with MMF and standard-dose CsA (3, 60). This effect cannot be attributed solely to lower CNI exposure, since Zuckermann et al observed a similar rate of CMV infection with everolimus and standard CsA versus everolimus with reduced CsA (4). Results comparing everolimus to MMF were not due to differences in CMV prophylaxis between treatment groups, which were similar in both arms or in different CMV serostatus for recipients and donors (3, 61).
There is evidence to suggest that mTOR is essential for CMV replication during late phases of the viral cycle (62) which could account for the inhibitor effect of everolimus on CMV infection rates. In vitro data indicate that mTOR acts through the mTOR complex 1 pathway to regulate memory T-cell differentiation (63), and that mTOR inhibitors exhibit immunostimulatory effects on memory CD8+ T-cells (64) that could improve the functional qualities of infection-induced memory cells.
Preservation of renal function
Evidence relating to a renal benefit of everolimus with reduced CNI from time of heart transplantation is less convincing. The bulk of data relating to use of everolimus to minimize CNI-related nephrotoxicity and protect renal function in heart transplant recipients derives from maintenance heart transplant populations: either randomized (8, 65) and non-randomized (10, 12-14) studies of everolimus with reduced-CNI, or non-randomized trials of conversion from CNI to everolimus In de novo heart transplant recipients, the Phase III study in which everolimus was administered with standard-exposure CsA showed inferior renal function in the everolimus treatment arm compared to the azathioprine group (30) ( Table 4 ). This is not unexpected in view of the known potentiation of the nephrotoxic effects of the CNI by mTOR inhibitors. More surprising was the absence of a renal benefit with CsA reduction in a trial of everolimus-treated de novo heart transplant patients randomized to reduced-or standard-exposure CsA (4) ( Table 4 One single-center, single-arm prospective study in 20 de novo heart transplant patients with significant renal dysfunction at transplant (estimated GFR <30mL/min/1.73m 2 ) has described outcomes using a CNI-free de novo regimen comprising everolimus or sirolimus with corticosteroids, with or without induction (33). Mean (SD) estimated GFR increased dramatically, from 28 (17)mL/min/1.73m 2 preoperatively to 64 (24)mL/min/1.73m 2 at month 6, with all four patients who had previously required dialysis becoming dialysis-free.
However, 55% of patients experienced rejection and 50% were eventually converted back to CNI therapy due to adverse events.
While these results are of interest, it seems unlikely that everolimusbased CNI-free immunosuppression is appropriate from the time of heart transplantation unless renal function is very poor.
Everolimus and malignancy
At present, reduction of malignancy risk is not generally a reason to select de novo therapy with everolimus and the evidence base for prevention of post-transplant cancer remains relatively limited.
Everolimus is, however, licensed for the treatment of advanced renal and breast tumors at higher doses than in post-transplant The largest randomized trial to date in de novo heart transplants, which compared everolimus with reduced CsA versus MMF with standard CsA (3) observed no significant difference in the incidence of sternal or non-sternal wound dehiscence between the two groups (Table 5 ). The Phase III trial (33) that compared everolimus at a fixed dose of 1.5mg or 3.0mg versus azathioprine, both with standardexposure CsA, found lymphocele to be significantly more frequent with everolimus (4.8% and 4.3% versus 0.9% with azathioprine) but the overall rate of all events was low and there were no significant differences in the occurrence of wound dehiscence at the sternal site or wound complications unrelated to the site of left ventricular assist device (69) . A pooled analysis of data from 1,009 heart transplant patients taking part in three trials (the Phase III trial Evaluation of delayed introduction of everolimus in heart transplant recipients, or an initial low-exposure mTOR inhibitor regimen, is ongoing (74).
Pericardial and pleural effusions
Pericardial effusion is a frequent occurrence after heart transplantation, with moderately to large effusions reported in approximately a fifth of recipients (73, (75) (76) (77) . Mortality and hospital stay are unaffected (75) (76) (77) , although one study suggested an association between pericardial effusions and acute rejection (78) .
Comparative randomized trials of everolimus versus MMF (3, 5) and versus azathioprine (30) have demonstrated a higher incidence of pericardial effusions in everolimus-treated patients although, importantly, cardiac tamponade was not more frequent in any of the studies (Table 5 ). The ongoing EVERHEART study in a de novo heart transplant population includes pericardial effusion as a pre-specified endpoint (74) , and will offer robust data. The risk of pleural effusions appears to be unaffected by use of everolimus compared to MMF (Table 5) . A target everolimus trough concentration range of 3-8ng/mL in de novo heart transplant recipients appears optimal when administered in combination with CNI therapy (3). Induction with a lymphocytedepleting agent such as rabbit ATG in patients receiving an everolimus-based regimen with relatively high CsA exposure (as in the A2310 trial) should be avoided due to risk of infection-related mortality (3) unless there are compelling clinical indications. Where everolimus is initiated at the time of heart transplantation, it is not known whether delayed introduction (e.g. until wound healing is complete) would be beneficial in avoiding incisional wound healing complications. While intuitively this is an appealing option, the most recent evidence (3) does not suggest that impaired healing is a clinical concern, and data from kidney transplantation indicates no benefit in delay (68) . If wound healing is a concern in high-risk patients (e.g. with high body mass index), low everolimus exposure could be a possible strategy but has not been investigated. It seems inadvisable to initiate everolimus in de novo heart transplant patients in whom repeat surgery is anticipated. 
